10th Feb 10
Cancer drug knocked back due to cost
by Paul Russell
A new drug aimed at treating advanced stage kidney cancer has been rejected by the NHS for use, according to a health watchdog.
While clinical trials show that everolimus (Afinitor) is effective at treating the cancer, it is expensive and there is limited data on how much it can extend people’s lives, according to the National Institute for Health and Clinical Excellence (NICE).
The drug is not a cure for kidney cancer, however its manufacturer Novartis said that patients usually are able to achieve a longer and better quality of life. It is suitable for patients who have failed on vascular endothelial growth factor-targeted therapy, a first line treatment for advanced renal cell carcinoma.
Research from pharmaceutical company Novartis shows that everolimus doubles the time without the tumour growing or death compared with a placebo (4.9 months, compared with 1.9 months). The drug costs £2,970 for 30 tablets, with an eight-week cycle costing about £5,544, according to figures released by NICE.
The pharmaceutical company offered a risk-sharing scheme to provide patients with the first treatment pack for free, followed by 5 per cent off further packs, however this was rejected.
NICE clinical and public health director, Professor Littlejohns said that the organisation was disappointed not to be able to recommend everolimus as a second line treatment option for patients with advanced renal cell carcinoma, but NHS resources are limited and NICE had to decide which treatments represent best value to the patients as well as the NHS.
Our Stories
- Retail veteran warns of high street “death spiral”
- Tesco exec who sold shares moved from role
- Tesco market share slips
- UK consumer confidence recovers
- Gary Speed talked of suicide before death
- Tesco scraps carbon-label pledge
- UK university applicant numbers fall 8.7%
- Stelios blasts easyJet bonuses
- Train staff to get Olympic bonus
- New house buyers drop by 10.5 per cent
- US economy sees fourth quarter growth increase
- Olympic Games will hit energy and transport plans
Popular Topics
afghanistan al qaeda Apple ASDA bank of england barack obama BBC british airways china david cameron Debenhams Egypt facebook george osborne Google India ipad iphone ivory coast japan Libya London M&S Marks & Spencer Morrisons nhs North Korea Office for National Statistics pakistan protests russia sainsburys Sainsbury’s South Korea terrorism Tesco Tunisia UK UK retailers UK retail news UK shopping us Waitrose Wikileaks x factorArchive
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- January 2009
